CN109662322A - 一种保肝护心血管的组合物及其制备方法 - Google Patents
一种保肝护心血管的组合物及其制备方法 Download PDFInfo
- Publication number
- CN109662322A CN109662322A CN201910106561.2A CN201910106561A CN109662322A CN 109662322 A CN109662322 A CN 109662322A CN 201910106561 A CN201910106561 A CN 201910106561A CN 109662322 A CN109662322 A CN 109662322A
- Authority
- CN
- China
- Prior art keywords
- composition
- powder
- parts
- peptide
- blood vessel
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 79
- 210000004185 liver Anatomy 0.000 title claims abstract description 56
- 210000004204 blood vessel Anatomy 0.000 title claims abstract description 32
- 238000002360 preparation method Methods 0.000 title claims abstract description 26
- 239000000843 powder Substances 0.000 claims abstract description 69
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 69
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims abstract description 66
- 241000237502 Ostreidae Species 0.000 claims abstract description 52
- 235000020636 oyster Nutrition 0.000 claims abstract description 52
- 240000008042 Zea mays Species 0.000 claims abstract description 34
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 claims abstract description 34
- 235000002017 Zea mays subsp mays Nutrition 0.000 claims abstract description 34
- 235000005822 corn Nutrition 0.000 claims abstract description 34
- 239000004310 lactic acid Substances 0.000 claims abstract description 34
- 235000014655 lactic acid Nutrition 0.000 claims abstract description 33
- 241000894006 Bacteria Species 0.000 claims abstract description 32
- 235000003145 Hippophae rhamnoides Nutrition 0.000 claims abstract description 30
- VDTNNGKXZGSZIP-UHFFFAOYSA-N carbutamide Chemical compound CCCCNC(=O)NS(=O)(=O)C1=CC=C(N)C=C1 VDTNNGKXZGSZIP-UHFFFAOYSA-N 0.000 claims abstract description 20
- 239000013078 crystal Substances 0.000 claims abstract description 20
- 235000013399 edible fruits Nutrition 0.000 claims abstract description 20
- 235000005979 Citrus limon Nutrition 0.000 claims abstract description 19
- 244000131522 Citrus pyriformis Species 0.000 claims abstract description 19
- 244000046146 Pueraria lobata Species 0.000 claims abstract description 16
- 235000010575 Pueraria lobata Nutrition 0.000 claims abstract description 16
- 235000005187 Taraxacum officinale ssp. officinale Nutrition 0.000 claims abstract description 15
- 235000006886 Zingiber officinale Nutrition 0.000 claims abstract description 14
- 235000008397 ginger Nutrition 0.000 claims abstract description 14
- 235000013305 food Nutrition 0.000 claims abstract description 13
- 239000002775 capsule Substances 0.000 claims abstract description 9
- 239000007787 solid Substances 0.000 claims abstract description 7
- 238000012545 processing Methods 0.000 claims abstract description 5
- 239000002994 raw material Substances 0.000 claims abstract description 5
- 244000273928 Zingiber officinale Species 0.000 claims abstract 4
- 241000229143 Hippophae Species 0.000 claims description 31
- 239000007788 liquid Substances 0.000 claims description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 22
- 235000019750 Crude protein Nutrition 0.000 claims description 18
- 102000004190 Enzymes Human genes 0.000 claims description 15
- 108090000790 Enzymes Proteins 0.000 claims description 15
- 230000007062 hydrolysis Effects 0.000 claims description 15
- 238000006460 hydrolysis reaction Methods 0.000 claims description 15
- 241000245665 Taraxacum Species 0.000 claims description 14
- 235000013372 meat Nutrition 0.000 claims description 14
- 239000002781 deodorant agent Substances 0.000 claims description 13
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 10
- 238000001035 drying Methods 0.000 claims description 10
- 239000000463 material Substances 0.000 claims description 10
- 108090000623 proteins and genes Proteins 0.000 claims description 10
- 239000000654 additive Substances 0.000 claims description 9
- 230000000996 additive effect Effects 0.000 claims description 9
- 102000004169 proteins and genes Human genes 0.000 claims description 9
- 238000001694 spray drying Methods 0.000 claims description 9
- 229910052799 carbon Inorganic materials 0.000 claims description 8
- 230000007071 enzymatic hydrolysis Effects 0.000 claims description 8
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 claims description 8
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 7
- 229920002494 Zein Polymers 0.000 claims description 7
- 108010055615 Zein Proteins 0.000 claims description 7
- 101000693530 Staphylococcus aureus Staphylokinase Proteins 0.000 claims description 6
- 230000009849 deactivation Effects 0.000 claims description 6
- 108090000145 Bacillolysin Proteins 0.000 claims description 4
- 229930091371 Fructose Natural products 0.000 claims description 4
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 4
- 240000006024 Lactobacillus plantarum Species 0.000 claims description 4
- 235000013965 Lactobacillus plantarum Nutrition 0.000 claims description 4
- 102000035092 Neutral proteases Human genes 0.000 claims description 4
- 108091005507 Neutral proteases Proteins 0.000 claims description 4
- 229940072205 lactobacillus plantarum Drugs 0.000 claims description 4
- 239000002120 nanofilm Substances 0.000 claims description 4
- 239000000758 substrate Substances 0.000 claims description 4
- 101800000068 Antioxidant peptide Proteins 0.000 claims description 3
- 238000000502 dialysis Methods 0.000 claims description 3
- 239000007921 spray Substances 0.000 claims description 3
- 208000011580 syndromic disease Diseases 0.000 claims description 3
- 241000186000 Bifidobacterium Species 0.000 claims description 2
- 206010013786 Dry skin Diseases 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims description 2
- 235000013312 flour Nutrition 0.000 claims description 2
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 claims 2
- 102000002322 Egg Proteins Human genes 0.000 claims 2
- 108010000912 Egg Proteins Proteins 0.000 claims 2
- 235000014103 egg white Nutrition 0.000 claims 2
- 210000000969 egg white Anatomy 0.000 claims 2
- VZQHRKZCAZCACO-PYJNHQTQSA-N (2s)-2-[[(2s)-2-[2-[[(2s)-2-[[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]propanoyl]amino]prop-2-enoylamino]-3-methylbutanoyl]amino]propanoic acid Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](C(C)C)NC(=O)C(=C)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCNC(N)=N VZQHRKZCAZCACO-PYJNHQTQSA-N 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 229960002737 fructose Drugs 0.000 claims 1
- 230000002526 effect on cardiovascular system Effects 0.000 abstract description 5
- 238000005516 engineering process Methods 0.000 abstract description 5
- 238000002474 experimental method Methods 0.000 abstract description 5
- 241001465754 Metazoa Species 0.000 abstract description 4
- 229940079593 drug Drugs 0.000 abstract description 3
- 239000003814 drug Substances 0.000 abstract description 3
- 238000002156 mixing Methods 0.000 abstract description 3
- 208000007848 Alcoholism Diseases 0.000 abstract description 2
- 201000007930 alcohol dependence Diseases 0.000 abstract description 2
- 238000009472 formulation Methods 0.000 abstract description 2
- 240000000950 Hippophae rhamnoides Species 0.000 abstract 1
- 240000001949 Taraxacum officinale Species 0.000 abstract 1
- 239000003826 tablet Substances 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 30
- 235000019441 ethanol Nutrition 0.000 description 18
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 17
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 16
- 239000012153 distilled water Substances 0.000 description 15
- 239000007864 aqueous solution Substances 0.000 description 14
- 230000000694 effects Effects 0.000 description 12
- 241000234314 Zingiber Species 0.000 description 10
- 229960004756 ethanol Drugs 0.000 description 10
- 239000011669 selenium Substances 0.000 description 10
- 241000699666 Mus <mouse, genus> Species 0.000 description 9
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 9
- 230000006870 function Effects 0.000 description 9
- 229910052711 selenium Inorganic materials 0.000 description 9
- 229940091258 selenium supplement Drugs 0.000 description 9
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 8
- 108010082126 Alanine transaminase Proteins 0.000 description 8
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 8
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 8
- 229960003180 glutathione Drugs 0.000 description 8
- 230000003078 antioxidant effect Effects 0.000 description 7
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 6
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 6
- 235000012000 cholesterol Nutrition 0.000 description 6
- 239000000284 extract Substances 0.000 description 6
- 210000005229 liver cell Anatomy 0.000 description 6
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 6
- 239000008108 microcrystalline cellulose Substances 0.000 description 6
- 229940016286 microcrystalline cellulose Drugs 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- 150000003626 triacylglycerols Chemical class 0.000 description 6
- 239000003963 antioxidant agent Substances 0.000 description 5
- 235000006708 antioxidants Nutrition 0.000 description 5
- 230000003647 oxidation Effects 0.000 description 5
- 238000007254 oxidation reaction Methods 0.000 description 5
- 239000013535 sea water Substances 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- 230000003064 anti-oxidating effect Effects 0.000 description 4
- 235000013361 beverage Nutrition 0.000 description 4
- BVTBRVFYZUCAKH-UHFFFAOYSA-L disodium selenite Chemical compound [Na+].[Na+].[O-][Se]([O-])=O BVTBRVFYZUCAKH-UHFFFAOYSA-L 0.000 description 4
- 230000014509 gene expression Effects 0.000 description 4
- 231100000753 hepatic injury Toxicity 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- -1 nicotinoyl Chemical group 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 229960001471 sodium selenite Drugs 0.000 description 4
- 235000015921 sodium selenite Nutrition 0.000 description 4
- 239000011781 sodium selenite Substances 0.000 description 4
- ULSUXBXHSYSGDT-UHFFFAOYSA-N tangeretin Chemical compound C1=CC(OC)=CC=C1C1=CC(=O)C2=C(OC)C(OC)=C(OC)C(OC)=C2O1 ULSUXBXHSYSGDT-UHFFFAOYSA-N 0.000 description 4
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 4
- 244000063299 Bacillus subtilis Species 0.000 description 3
- 235000014469 Bacillus subtilis Nutrition 0.000 description 3
- 239000005715 Fructose Substances 0.000 description 3
- 108010024636 Glutathione Proteins 0.000 description 3
- 108010007622 LDL Lipoproteins Proteins 0.000 description 3
- 102000007330 LDL Lipoproteins Human genes 0.000 description 3
- 102000019197 Superoxide Dismutase Human genes 0.000 description 3
- 108010012715 Superoxide dismutase Proteins 0.000 description 3
- LKDRXBCSQODPBY-ZXXMMSQZSA-N alpha-D-fructopyranose Chemical compound OC[C@]1(O)OC[C@@H](O)[C@@H](O)[C@@H]1O LKDRXBCSQODPBY-ZXXMMSQZSA-N 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000003859 lipid peroxidation Effects 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000001100 (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chroman-4-one Substances 0.000 description 2
- FTVWIRXFELQLPI-ZDUSSCGKSA-N (S)-naringenin Chemical compound C1=CC(O)=CC=C1[C@H]1OC2=CC(O)=CC(O)=C2C(=O)C1 FTVWIRXFELQLPI-ZDUSSCGKSA-N 0.000 description 2
- MSWZFWKMSRAUBD-GASJEMHNSA-N 2-amino-2-deoxy-D-galactopyranose Chemical compound N[C@H]1C(O)O[C@H](CO)[C@H](O)[C@@H]1O MSWZFWKMSRAUBD-GASJEMHNSA-N 0.000 description 2
- 208000007082 Alcoholic Fatty Liver Diseases 0.000 description 2
- 102000016938 Catalase Human genes 0.000 description 2
- 108010053835 Catalase Proteins 0.000 description 2
- 241000721047 Danaus plexippus Species 0.000 description 2
- 206010016262 Fatty liver alcoholic Diseases 0.000 description 2
- 206010019668 Hepatic fibrosis Diseases 0.000 description 2
- 235000003935 Hippophae Nutrition 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 208000031816 Pathologic Dilatation Diseases 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 239000005864 Sulphur Substances 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 208000026594 alcoholic fatty liver disease Diseases 0.000 description 2
- MSWZFWKMSRAUBD-UHFFFAOYSA-N beta-D-galactosamine Natural products NC1C(O)OC(CO)C(O)C1O MSWZFWKMSRAUBD-UHFFFAOYSA-N 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 208000010706 fatty liver disease Diseases 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- AIONOLUJZLIMTK-AWEZNQCLSA-N hesperetin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O)=CC(O)=C2C(=O)C1 AIONOLUJZLIMTK-AWEZNQCLSA-N 0.000 description 2
- AIONOLUJZLIMTK-UHFFFAOYSA-N hesperetin Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(O)=CC(O)=C2C(=O)C1 AIONOLUJZLIMTK-UHFFFAOYSA-N 0.000 description 2
- 235000010209 hesperetin Nutrition 0.000 description 2
- 229960001587 hesperetin Drugs 0.000 description 2
- FTODBIPDTXRIGS-UHFFFAOYSA-N homoeriodictyol Natural products C1=C(O)C(OC)=CC(C2OC3=CC(O)=CC(O)=C3C(=O)C2)=C1 FTODBIPDTXRIGS-UHFFFAOYSA-N 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 229920006008 lipopolysaccharide Polymers 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- WGEYAGZBLYNDFV-UHFFFAOYSA-N naringenin Natural products C1(=O)C2=C(O)C=C(O)C=C2OC(C1)C1=CC=C(CC1)O WGEYAGZBLYNDFV-UHFFFAOYSA-N 0.000 description 2
- 235000007625 naringenin Nutrition 0.000 description 2
- 229940117954 naringenin Drugs 0.000 description 2
- 150000008442 polyphenolic compounds Chemical class 0.000 description 2
- 235000013824 polyphenols Nutrition 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 230000028527 righting reflex Effects 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 235000008603 tangeritin Nutrition 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- 102100036009 5'-AMP-activated protein kinase catalytic subunit alpha-2 Human genes 0.000 description 1
- 208000021959 Abnormal metabolism Diseases 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- 206010003084 Areflexia Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 206010053155 Epigastric discomfort Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000006587 Glutathione peroxidase Human genes 0.000 description 1
- 108700016172 Glutathione peroxidases Proteins 0.000 description 1
- 108010010234 HDL Lipoproteins Proteins 0.000 description 1
- 102000015779 HDL Lipoproteins Human genes 0.000 description 1
- 238000013218 HFD mouse model Methods 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 206010019842 Hepatomegaly Diseases 0.000 description 1
- 101000783681 Homo sapiens 5'-AMP-activated protein kinase catalytic subunit alpha-2 Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000003777 Interleukin-1 beta Human genes 0.000 description 1
- 108090000193 Interleukin-1 beta Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 108010028554 LDL Cholesterol Proteins 0.000 description 1
- 102000018745 NF-KappaB Inhibitor alpha Human genes 0.000 description 1
- 108010052419 NF-KappaB Inhibitor alpha Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108010038807 Oligopeptides Proteins 0.000 description 1
- 102000015636 Oligopeptides Human genes 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 102000023984 PPAR alpha Human genes 0.000 description 1
- 108010028924 PPAR alpha Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 102000008221 Superoxide Dismutase-1 Human genes 0.000 description 1
- 108010021188 Superoxide Dismutase-1 Proteins 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- FZPYMZUVXJUAQA-ZDUSSCGKSA-N Turmerone Chemical compound CC(C)=CC(=O)C[C@H](C)C1=CCC(C)=CC1 FZPYMZUVXJUAQA-ZDUSSCGKSA-N 0.000 description 1
- FZPYMZUVXJUAQA-UHFFFAOYSA-N Turmerone Natural products CC(C)=CC(=O)CC(C)C1=CCC(C)=CC1 FZPYMZUVXJUAQA-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- XOCANRBEOZQNAQ-KBPBESRZSA-N alpha-turmerone Natural products O=C(/C=C(\C)/C)C[C@H](C)[C@H]1C=CC(C)=CC1 XOCANRBEOZQNAQ-KBPBESRZSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- 230000002075 anti-alcohol Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- QUQPHWDTPGMPEX-UTWYECKDSA-N aurantiamarin Natural products COc1ccc(cc1O)[C@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1 QUQPHWDTPGMPEX-UTWYECKDSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 150000005693 branched-chain amino acids Chemical class 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 229960000935 dehydrated alcohol Drugs 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 238000002101 electrospray ionisation tandem mass spectrometry Methods 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000036732 histological change Effects 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 1
- 235000008696 isoflavones Nutrition 0.000 description 1
- 235000015141 kefir Nutrition 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000006372 lipid accumulation Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 108010022197 lipoprotein cholesterol Proteins 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 210000002311 liver mitochondria Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000006371 metabolic abnormality Effects 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- HXTFHSYLYXVTHC-AJHDJQPGSA-N narirutin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC=2C=C3O[C@@H](CC(=O)C3=C(O)C=2)C=2C=CC(O)=CC=2)O1 HXTFHSYLYXVTHC-AJHDJQPGSA-N 0.000 description 1
- HXTFHSYLYXVTHC-ZPHOTFPESA-N narirutin Natural products C[C@@H]1O[C@H](OC[C@H]2O[C@@H](Oc3cc(O)c4C(=O)C[C@H](Oc4c3)c5ccc(O)cc5)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O HXTFHSYLYXVTHC-ZPHOTFPESA-N 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 235000021110 pickles Nutrition 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 235000019419 proteases Nutrition 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 150000008130 triterpenoid saponins Chemical class 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23J—PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
- A23J1/00—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites
- A23J1/04—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites from fish or other sea animals
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23J—PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
- A23J1/00—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites
- A23J1/12—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites from cereals, wheat, bran, or molasses
- A23J1/125—Obtaining protein compositions for foodstuffs; Bulk opening of eggs and separation of yolks from whites from cereals, wheat, bran, or molasses by treatment involving enzymes or microorganisms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23J—PROTEIN COMPOSITIONS FOR FOODSTUFFS; WORKING-UP PROTEINS FOR FOODSTUFFS; PHOSPHATIDE COMPOSITIONS FOR FOODSTUFFS
- A23J3/00—Working-up of proteins for foodstuffs
- A23J3/30—Working-up of proteins for foodstuffs by hydrolysis
- A23J3/32—Working-up of proteins for foodstuffs by hydrolysis using chemical agents
- A23J3/34—Working-up of proteins for foodstuffs by hydrolysis using chemical agents using enzymes
- A23J3/341—Working-up of proteins for foodstuffs by hydrolysis using chemical agents using enzymes of animal proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Polymers & Plastics (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Marine Sciences & Fisheries (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
本发明涉及一种保肝护心血管的组合物及其制备方法,食品加工技术领域。其包括结晶果糖、乳酸菌粉、葛根粉、陈皮、牡蛎肽、沙棘粉、蒲公英、柠檬、姜和玉米肽,充分混匀后得到所述产品保肝护心血管的组合物。其可以制备成片剂、胶囊或固体粉末作食医两用。本发明提供的保肝护心血管的解酒组合物采用常规药食两用的原料,相对于现有技术,配方简单有效,食用更安全,可长期食用;经动物实验证明,相对于传统配方,其具有更好的解酒护肝保护心血管的效果。
Description
技术领域
本发明涉及一种保肝护心血管的组合物及其制备方法,食品加工技术领域。
背景技术
酒精性脂肪肝(ALD)是目前常见的由长期酒精摄入而导致的一种疾病。众所周知,慢性酒精消耗与代谢性肝病发展存在明显关联。其原因在于酒的主要成分乙醇被人体吸收后,在体内会部分转化为乙醛,乙醛对人体具有一定的毒性,同时在代谢过程中,会生成较多的活性氧(ROS),从而降低线粒体GSH(mtGSH)含量,使这些细胞器更易受ROS损伤,同时也会增加甘油三酯(TC)浓度、丙氨酸转氨酶(ALT),天冬氨酸转氨酶(AST)上升,使得肝脏脂肪变性,最后导致肝脏纤维化。
在开菲尔和陈年泡菜水中筛选的乳酸菌具有特殊的降低胆固醇效果,其对脂变肝细胞起到修复的作用。乳酸菌可以显著降低血清总胆固醇和低密度脂蛋白胆固醇含量,显著降低高脂饮食小鼠的肝脏总胆固醇和甘油三酯,增加粪便胆固醇和胆汁酸的排出,从而起到了保护肝脏以及心血管的效果。
沙棘的保肝成分主要是其中的沙棘多糖提取物,其通过抑制TLR4-NF-κB信号通路来保护由脂多糖(LPS)和盐酸d-半乳糖胺(d-GalN)导致的肝衰竭。同时可以用沙棘多糖可以降低丙二醛(MDA)含量,增加超氧化物歧化酶(SOD)和谷胱甘肽过氧化物酶(GSH-PX)活性,从而达到保肝的作用。
陈皮或橙皮中提取物Narirutin对乙醇诱导的肝损伤具有很好的保护作用。陈皮或橙皮的摄入可以抑制肝肿大,降低肝脏中的TG(甘油三酯)和TC(胆固醇)的浓度达到30%。同时陈皮中的多种提取物,使得血清中的丙氨酸转氨酶(ALT),天冬氨酸转氨酶(AST)含量显著降低,而酶促抗氧化SOD活性和非酶抗氧化剂GSH水平含量也会显著增加。针对肝脏炎症方面,陈皮也有较好的作用,其抑制促炎细胞因子例如IκB-α,TNF-α,IL-1β和IL-6的含量来修复肝脏功能,其在保肝方面具有非常明显的优势。G-橙皮苷通过抑制血管中烟酰胺腺嘌呤二核苷酸磷酸氧化酶的表达来减少氧化应激,从而改善自发性高血压,尚未发现在该功能组合物中使用陈皮。
柠檬中的柑橘黄酮柚皮素和橙皮素可以改善肝脏的抗氧化状态和肝细胞脂膜的组成,柑橘黄酮柚皮素可增加抗氧化酶(SOD1和2,谷胱甘肽过氧化物酶-GPx和GR)和肝脏谷胱甘肽(GSH)的活性增加,而橙皮素则是可以增加过氧化氢酶(CAT)的活性,从而达到保保肝脏的作用。同时其可以显着降低血清胆固醇,甘油三酯,低密度脂蛋白水平,同时可使得高密度脂蛋白增加,其中甘油三酯含量降低约30%,从而达到保护心血管的作用,同样尚未发现在该功能组合物中使用柠檬。
牡蛎中保肝主要成分为以下两类,主要为多酚类和具有抗氧化性的短肽。牡蛎中的多酚可以抑制铜介导的低密度脂蛋白(LDL)的氧化,提高肝脏细胞活力。而通过蛋白酶酶解牡蛎的寡肽同时具有抑癌特性,癌细胞生长得到明显抑制,在之前的专利中尚未有人提及。
玉米肽,作为抗氧化肽有显著的O2-·和·OH-自由基有很强的清除能力,对急性酒精性肝损伤有一定的保护作用。其中主要可通过降低MDA含量明显降低,增加GSH-PX活力从而达到保肝的作用。另外其可通过改善血清中的F值(支链氨基酸/芳香族氨基酸),起到保护肝脏的作用。
在解酒制品中加入结晶果糖,可以发挥果糖的多种功效。果糖吸收代谢迅速,可及时弥补酒精性的低血糖。果糖的代谢过程路径短,耗能低,不产生乳酸,在肝脏缺氧情况下仍可代谢,肝脏负担轻。果糖能促进体内醇的分解,抑制蛋白质消耗,减少毒性最大的中间产物乙醛的停留时间。果糖还可减少酒精对肝细胞的缺氧损伤,减少缺氧肝细胞的死亡,在缺氧消除后及时恢复肝细胞的代谢能力。
葛根中的提取物异黄酮糖苷和三萜皂苷成分可有效改善乙醇引起的异常代谢和肝损伤。1.其可通过调节PPARα通路的靶基因的表达,改善肝脏线粒体功能;2.其较好的抗氧化作用,可不同程度地清除体内自由基,,减少ROS对肝脏的损害,降低肝细胞脂质过氧化程度,提高体内抗氧化酶的活性,维持肝细胞膜的结构和功能完整。
蒲公英中的提取物可通过调节AMPK途径显著抑制肝脏中的脂质积累,降低身体对胰岛素的耐性,同时可显著抑制甘油三酯、总胆固醇、胰岛素、空腹血清血糖水平,通过提高抗氧化能力和降低脂质过氧化作用起到保护的作用。
姜的提取物改善基因表达改变和组织学改变,改善了不良的脂质特征和肝酶的变化,作为超氧阴离子的有效清除剂,姜黄酮在较高浓度下抑制肝微粒体脂质过氧化。
发明内容
本发明的目的是解决现有技术中解酒保肝产品存在的效果不佳,没有保护心血管作用的问题,提供一种保肝护心血管的组合物及其制备方法。其通过乳酸菌粉和葛根、陈皮、柠檬、牡蛎肽、玉米肽、沙棘具有的协同作用,控制体内基因表达,降低ROS含量,明显减轻酒精导致的肝损伤作用,能够显著抑制酒精性脂肪肝的肝纤维化,且陈皮、柠檬、牡蛎肽能够显著的保护心血管。
本发明的技术方案,一种保肝护心血管的组合物,配方比例按重量份计如下:结晶果糖5~30份;乳酸菌粉5~30份;葛根粉8~15份;陈皮10~15份;牡蛎肽4~8份;沙棘粉8~15份;蒲公英3~8份;柠檬5~18份;姜3~8份;玉米肽3~10份。
进一步地,所述结晶果糖为食用级结晶果糖。
进一步地,所述乳酸菌粉为冻干乳酸菌粉。
优选的,包括植物乳杆菌粉或双歧杆菌粉。
进一步地,所述牡蛎肽为新鲜牡蛎培养后,采用中性蛋白酶酶解,脱腥,喷雾干燥所得。
进一步地,所述玉米肽为碱性蛋白酶水解玉米醇溶蛋白,低温干燥后得到的玉米肽。
进一步地,还包括食品辅料或添加剂;所述食品辅料或添加剂按质量百分比计占保肝护心血管的组合物的60%~75%。
进一步地,一种保肝护心血管的片剂,其包括所述保肝护心血管的组合物。
进一步地,一种保肝护心血管的胶囊,其包括所述保肝护心血管的组合物。
进一步地,一种保肝护心血管的固体粉末,其包括所述保肝护心血管的组合物。
进一步地,所述保肝护心血管的组合物的制备方法,步骤如下:
(1)玉米肽的制备:为碱性蛋白酶水解玉米醇溶蛋白,低温干燥后得到的玉米肽。具体的,所述玉米肽可来源于Alcalase2.4FG碱性蛋白酶水解玉米醇溶蛋白得到的抗氧化短肽。
(2)牡蛎肽的制备:将新鲜牡蛎培养后,采用中性蛋白酶在以下条件酶解得到粗蛋白,将粗蛋白液采用乳酸菌、酵母、活性炭三者联用脱腥处理,喷雾干燥后,得牡蛎-硒-寡肽蛋白粉,简称牡蛎肽;所述中性蛋白酶具体为枯草芽孢杆菌的中性蛋白酶。
(3)沙棘粉的制备:将沙棘洗净后榨汁得到沙棘原浆,低温浓缩得到沙棘浓浆,将沙棘浓浆进行喷雾干燥后得到沙棘粉;
(4)葛根粉、陈皮、蒲公英、柠檬皮/肉、姜粉的制备:将所述原料分别洗净后,磨粉机中加水磨碎,最后50~70℃低温烘干18~36小时,分别制得相应干粉;
(5)复配:将结晶果糖5~30份;乳酸菌粉5~30份;葛根粉8~15份;陈皮10~15份;牡蛎肽4~8份;沙棘粉8~15份;蒲公英3~8份;柠檬5~18份;姜3~8份和玉米肽3~10份,充分混合后得到成品保肝护心血管的组合物。
步骤(1)所述玉米肽的制备过程具体如下:取碱性蛋白酶水解玉米醇溶蛋白;酶解条件首先在pH 7-9、40-60℃下酶解2.5~3.5小时,随后在pH 6.0~8.0、40~50℃下酶解1.5~2.5小时,得到粗酶液;将粗酶液过3kD分子膜,透析得到玉米抗氧化肽溶液,浓缩喷雾干燥,进风温度160~200℃,出风温度60~90℃,即得到玉米肽。
步骤(2)所述牡蛎肽的制备过程具体如下:
a、将新鲜牡蛎培养后,取出牡蛎肉搅碎均浆,采用中性蛋白酶酶解,酶解pH为5.0~7.0,酶添加量/底物比例(E/S)为1.6~2.0%,水解温度60~70℃,水解时间为60~80min,得到粗蛋白液;
b、所述粗蛋白液在90℃环境下灭酶10~20min;
c、将灭酶后的粗蛋白液采用乳酸菌、酵母和活性炭三者联用脱腥处理;脱腥条件:脱腥处理时,酵母:乳酸菌的添加质量比为1:2~5,两者的添加总量为粗蛋白液总质量的1.0%~2.0%,随后在25~40℃下脱腥处理15~30min;处理后,继续添加活性炭,添加量为粗蛋白液总质量的1.0%~2.0%,在30~50℃下继续脱腥30~60min,得到脱腥蛋白液;
d、脱腥蛋白液喷雾干燥后,得牡蛎-硒-寡肽蛋白粉,简称牡蛎肽;喷雾干燥为进风温度160~200℃,60~90℃。
进一步地,所述新鲜牡蛎培养的过程如下:将鲜牡蛎置于加入无机硒(亚硒酸钠)的海水中,海水中的亚硒酸钠浓度为12-16μg/mL,将牡蛎在此海水中培养2-4d。
进一步地,在4℃以下对牡蛎肉进行搅碎匀浆操作。
进一步地,所述牡蛎肽的构成为Pro-Val-MetSe-Gly-Asp,其中甲硫氨酸中的硫元素被替代成硒元素。
本发明的有益效果:本发明提供的保肝护心血管的解酒组合物采用常规药食两用的原料,相对于现有技术,配方简单有效,食用更安全,可长期食用;经动物实验证明,相对于传统配方,其具有更好的解酒保肝保护心血管的效果。
附图说明
图1是本发明制备方法示意图。
具体实施方式
下面通过实例的方式来进一步说明本发明,但是并不因此将本发明限制在所述的实施例范围之中。下列实施例中未注明具体条件的实验方法,均按照常规方法和条件,或按照商品说明书选择。
乳酸菌粉的获取:乳酸菌粉从市场进行购买,其中的乳酸菌为植物乳杆菌,具体为君乐宝乳酸菌粉。
结晶果糖的获取:结晶果糖(食用级)从市场进行购买,具体购自山西西王糖业股份有限公司。
实施例1保肝护心血管的组合物原料制备:
(1)玉米抗氧化肽的获取:所述玉米肽可来源于Alcalase2.4FG碱性蛋白酶水解玉米醇溶蛋白得到的抗氧化短肽。
酶解条件:第一步,pH 8.5和55℃下进行3小时;第二步,pH 7.0和45℃下进行2小时。酶解后进行灭酶,粗酶解液通过3kD分子膜,透析收集3kD分子量以下的组分,得到玉米抗氧化肽溶液;浓缩喷雾干燥,进风温度180℃,出风温度80℃,即得到玉米肽。
(2)牡蛎肽的获取:实施例所述牡蛎肽具体为牡蛎-硒-寡肽,为水解富硒的牡蛎中蛋白质得到的新型抗氧化短肽,通过高产枯草芽孢杆菌的中性蛋白酶水解得到。
a、富硒牡蛎制备:将市场购买的鲜牡蛎置于加入无机硒(亚硒酸钠)的海水中,海水中的亚硒酸钠浓度为12-16μg/mL,将牡蛎在此海水中培养3d,总硒含量从0.64μg/g(鲜重)上升至3.99μg/g,其中牡蛎肉有机硒的含量从0.34μg/g上升至3.23μg/g。
b、牡蛎-硒-寡肽制备:将步骤a所得富硒牡蛎肉取出,在4℃情况下进行搅碎匀浆操作,采用一定的酶和底物的比例与酶解条件进行酶解,制备含有特定抗氧化性的牡蛎-硒-寡肽。
所述最优的酶解条件为:种类为由枯草芽孢杆菌生产的中性蛋白酶(购自无锡天兴生物制品有限公司),酶解的初期最佳的pH为6.0,酶添加量/底物比例为1.8%,水解温度65℃,水解时间为70min得到牡蛎粗蛋白,在90℃环境下灭酶15min,得到粗蛋白液;
c、粗蛋白新型有效成分鉴定:将步骤b所述粗蛋白液使用3kDa的分子膜截留后,采用交联葡聚糖G-15凝胶过滤色谱法后发现,230nm处出峰,且对羟基自由基有明显的去除作用。在通过反相高效液相色谱RC-HPLC后可得到单独的短肽。通过纳米ESI-MS/MS鉴定肽链的构成为Pro-Val-MetSe-Gly-Asp,其中甲硫氨酸中的硫元素被替代成硒元素,从而形成了牡蛎-硒-寡肽,这种含硒的抗氧化性肽和目前BLAST中列出的其他抗氧化肽没有显著的相似性,可认为是一种在该反应条件下得到的一种新型抗氧化肽。
d、牡蛎-硒-寡肽脱腥工艺:采用乳酸菌-酵母-活性炭三者联用对牡蛎粗蛋白液进行脱腥处理,先使用酵母-乳酸菌混菌发酵脱腥处理,再添加活性炭进行脱腥处理。
酵母:乳酸菌比例为1:2.6,总量为粗蛋白的1.5%,脱腥温度为30摄氏度,时间为20min,后添加活性炭添加量为1.5%,温度40℃,时间为40min,得到的产品有清新香味,基本没有腥味。OD550值为0.250。
e、牡蛎-硒-寡肽干燥工艺:将脱腥后的牡蛎-硒-寡肽液进行浓缩,喷雾干燥得到牡蛎-硒-寡肽粉末,更加具体的喷雾干燥为进风温度180℃,出风温度80℃,牡蛎-硒-寡肽在产品中简称为牡蛎肽。
(3)其余原料均可从市场购买或者对原药食两用产品进行清洗粉碎干燥即可。
其中,葛根粉、陈皮、蒲公英、柠檬皮/肉和姜均为将其洗净后,磨粉机中加水磨碎后,再进行低温烘干,烘干条件为60℃,24小时制得干粉。
沙棘则是将其榨汁得到沙棘原浆,将低温浓缩后得到沙棘浓浆,将浓浆进行喷雾干燥后得到沙棘浓缩粉,简称沙棘粉。
具体工艺如图1所示。
实施例2
称取乳酸菌粉100g(含微晶纤维素80%)、结晶果糖300g、葛根粉150g、陈皮110g、牡蛎肽50g、沙棘粉90g、蒲公英50g、柠檬皮/肉50g、姜50g、玉米肽50g。分别过40目筛,将上述物料加入造粒机中混合。经过压片机压片得到片剂。
实施例3
称取乳酸菌粉150g(含微晶纤维素80%)、结晶果糖250g、葛根粉150g、陈皮110g、牡蛎肽50g、沙棘粉90g、蒲公英50g、柠檬皮/肉50g、姜50g、玉米肽50g。分别过40目筛,将上述物料加入造粒机中混合,使用胶囊填充剂灌制0号胶囊,得到胶囊制剂。
实施例4
称取乳酸菌粉200g(含微晶纤维素80%)、结晶果糖200g、葛根粉150g、陈皮110g、牡蛎肽50g、沙棘粉90g、蒲公英50g、柠檬皮/肉50g、姜50g、玉米肽50g。分别过40目筛,将上述物料加入造粒机中混合,使用胶囊填充剂灌制0号胶囊,得到胶囊制剂。
实施例5
称取乳酸菌粉200g(含微晶纤维素80%)、结晶果糖150g、葛根粉150g、陈皮130g、牡蛎肽50g、沙棘粉90g、蒲公英50g、柠檬皮/肉70g、姜50g、玉米肽60g。分别过40目筛,将上述物料加入造粒机中混合。经过压片机压片得到片剂。
实施例6
称取乳酸菌粉200g(含微晶纤维素80%)、结晶果糖150g、葛根粉100g、陈皮100g、牡蛎肽70g、沙棘粉120g、蒲公英50g、柠檬皮/肉100g、姜50g、玉米肽60g。分别过40目筛,将上述物料加入造粒机中混合。分装包装密封得到固体饮料,该固体饮料可溶于水中,亦可作冲剂使用。
实施例7
乳酸菌粉150g(含微晶纤维素80%)、结晶果糖150g、葛根粉120g、陈皮150g、牡蛎肽70g、沙棘粉90g、蒲公英50g、柠檬皮/肉80g、姜50g、玉米肽90g。分别过40目筛,将上述物料加入造粒机中混合。分装密封得到固体饮料,该固体饮料可溶于水中,亦可作冲剂使用。
应用实施例1
以下通过小鼠实验,对实施例2-7制备所得保肝护心血管效果进行说明:
1、试剂:植物乳杆菌为君乐宝乳酸菌粉、玉米肽、牡蛎肽通过上述的蛋白酶酶解获得。无水乙醇,分析纯:购自国药集团化学试剂有限公司。
受试组合物:按实施例2-7处方配置
2、实验动物:ICR小鼠,动物级别:清洁级。
3、实验方案:长效保肝护心血管效果试验
空白组:不给予乙醇和组合物;
对照组:仅给予乙醇。
组合物组0:取结晶果糖1.25g,加蒸馏水配制成10mL的水溶液。
组合物组1:称取实例1组合物1.25g,加蒸馏水配制成10mL的水溶液。
组合物组2:称取实例2组合物1.25g,加蒸馏水配制成10mL的水溶液。
组合物组3:称取实例3组合物1.25g,加蒸馏水配制成10mL的水溶液。
组合物组4:称取实例4组合物1.25g,加蒸馏水配制成10mL的水溶液。
组合物组5:称取实例5组合物1.25g,加蒸馏水配制成10mL的水溶液。
组合物组6:称取实例6组合物1.25g,加蒸馏水配制成10mL的水溶液。
取体重为27-28g的8周龄雄性ICR小鼠在动物实验研究实验室中适应1周,并随机分成6组。每组10只小鼠。将小鼠单独置于塑料笼中,并在22±2℃的室温和55±5%的相对湿度下每天进行12小时光照、黑暗循环。空白组对其使用的AIN-93G饮食和水。乙醇对照组每日胃内注射6.5g乙醇/kg体重。将乙醇稀释至40%以防止急性胃刺激。每次的乙醇和该组合物均为共同给药,该喂养实验持续8周。
测定8周后的小鼠肝脏中的甘油三酯含量(TG)、总胆固醇(TC)、天冬氨酸转氨酶(AST)和丙氨酸转氨酶(ALT),以及抗氧化成分谷胱甘肽(GSH)含量。具体参数如表1所示。
表1
根据以上数据可以发现,给予组合物后,相比于对照组,甘油三酯和胆固醇含量下降与空白组接近,这说明有较好的保护心血管的功效。同时血清中的天冬氨酸转氨酶(AST)和丙氨酸转氨酶(ALT)同样呈现了明显下降的趋势,这说明的其具有明显的保护肝脏的功能,同时其中的含有抗氧化能力的谷胱甘肽GSH的含量增加,说明其可通过降低ROS的含量达到防止肝脏纤维化的功能。说明结晶果糖和乳酸菌粉、陈皮、柠檬、牡蛎肽、玉米肽等本组合物成分具有协同作用。
应用实施例2快速解酒功效实例
对照组:仅给予乙醇
组合物0:取结晶果糖1.5g,加蒸馏水配制成10mL的水溶液。
组合物1:称取实例1组合物1.5g,加蒸馏水配制成10mL的水溶液。
组合物2:称取实例2组合物1.5g,加蒸馏水配制成10mL的水溶液。
组合物3:称取实例3组合物1.5g,加蒸馏水配制成10mL的水溶液。
组合物4:称取实例4组合物1.5g,加蒸馏水配制成10mL的水溶液。
组合物5:称取实例5组合物1.5g,加蒸馏水配制成10mL的水溶液。
组合物6:称取实例6组合物1.5g,加蒸馏水配制成10mL的水溶液。
取体重27-28g的雄性ICR小鼠90只,随机分为9组,每组10只,分别为空白、对照组,服用组合物0-6组。禁食不禁水12h后,空白组灌胃蒸馏水,其他各组给予本组合物,灌胃体积均为200μL/10g。30min后,各组小鼠灌胃40%乙醇(200μL/10g)。记录从小鼠给酒后到出现翻正反射消失(即醉酒)的时间;翻正反射恢复(即醒酒)的时间,比较各组小鼠醉酒和醒酒情况。具体参数如表2所示。
表2
组别 | 醉酒时间(min) | 醒酒时间(min) |
对照组 | 13.25±8.52 | 252.56±29.36 |
组合物0 | 18.22±8.53 | 215.96±30.15 |
组合物1 | 23.95±7.12 | 205.32±38.12 |
组合物2 | 25.56±6.67 | 192.18±26.12 |
组合物3 | 33.18±10.25 | 180.56±25.15 |
组合物4 | 38.83±7.60 | 175.63±31.62 |
组合物5 | 46.86±4.11 | 160.63±20.51 |
组合物6 | 46.52±5.16 | 158.75±35.23 |
相比于对照组,给予组合物1-6,小鼠的醒酒时间显著缩短,相比于组合物0,本发明的组合物4-6组效果显著较好,因此,给予组合物4-6组的对快速醒酒方面有的明显的效果,同时结晶果糖和本发明的组合物联用具有明显的协同效果。
Claims (10)
1.一种保肝护心血管的组合物,其特征是配方比例按重量份计如下:结晶果糖5~30份;乳酸菌粉5~30份;葛根粉8~15份;陈皮10~15份;牡蛎肽4~8份;沙棘粉8~15份;蒲公英3~8份;柠檬5~18份;姜3~8份;玉米肽3~10份。
2.如权利要求1所述保肝护心血管的组合物,其特征是:所述结晶果糖为食用级结晶果糖。
3.如权利要求1所述保肝护心血管的组合物,其特征是:所述乳酸菌粉为冻干乳酸菌粉;优选的,包括植物乳杆菌粉或双歧杆菌粉。
4.如权利要求3所述保肝护心血管的组合物,其特征是:所述牡蛎肽为新鲜牡蛎培养后,采用中性蛋白酶酶解脱腥,喷雾干燥所得。
5.如权利要求3所述保肝护心血管的组合物,其特征是:所述玉米肽为碱性蛋白酶水解玉米醇溶蛋白,低温干燥后得到的玉米肽。
6.如权利要求1所述保肝护心血管的组合物,其特征是:还包括食品辅料或添加剂;所述食品辅料或添加剂按质量百分比计占保肝护心血管的组合物的60%~75%。
7.权利要求1-6之一所述保肝护心血管的组合物,其特征是:应用于制备保肝解酒的片剂、胶囊或固体粉末。
8.权利要求1所述保肝护心血管的组合物的制备方法,其特征是步骤如下:
(1)玉米肽的制备:为碱性蛋白酶水解玉米醇溶蛋白,低温干燥后得到的玉米肽;
(2)牡蛎肽的制备:将新鲜牡蛎培养后,采用中性蛋白酶在以下条件酶解得到粗蛋白,将粗蛋白液采用乳酸菌、酵母、活性炭三者联用脱腥处理,喷雾干燥后,得牡蛎-硒-寡肽蛋白粉,简称牡蛎肽;
(3)沙棘粉的制备:将沙棘洗净后榨汁得到沙棘原浆,低温浓缩得到沙棘浓浆,将沙棘浓浆进行喷雾干燥后得到沙棘粉;
(4)葛根粉、陈皮、蒲公英、柠檬皮/肉、姜粉的制备:将所述原料分别洗净后,磨粉机中加水磨碎,最后50~70℃低温烘干18~36小时,分别制得相应干粉;
(5)复配:将结晶果糖5~30份;乳酸菌粉5~30份;葛根粉8~15份;陈皮10~15份;牡蛎肽4~8份;沙棘粉8~15份;蒲公英3~8份;柠檬5~18份;姜3~8份和玉米肽3~10份,充分混合后得到成品保肝护心血管的组合物。
9.如权利要求8所述保肝护心血管的组合物的制备方法,其特征是步骤(1)所述玉米肽的制备过程具体如下:取碱性蛋白酶水解玉米醇溶蛋白;酶解条件首先在pH 7-9、40-60℃下酶解2.5~3.5小时,随后在pH 6.0~8.0、40~50℃下酶解1.5~2.5小时,得到粗酶液;将粗酶液过3kD分子膜,透析得到玉米抗氧化肽溶液,浓缩喷雾干燥,进风温度160~200℃,出风温度60~90℃,即得到玉米肽。
10.如权利要求8所述保肝护心血管的组合物的制备方法,其特征是步骤(2)所述牡蛎肽的制备过程具体如下:
a、将新鲜牡蛎培养后,取出牡蛎肉搅碎均浆,采用中性蛋白酶酶解,酶解pH为5.0~7.0,酶添加量/底物比例E/S为1.6%~2.0%,水解温度60~70℃,水解时间为60~80 min,得到粗蛋白液;
b、所述粗蛋白液在90℃环境下灭酶10~20min;
c、将灭酶后的粗蛋白液采用乳酸菌、酵母和活性炭三者联用脱腥处理;脱腥条件:脱腥处理时,酵母:乳酸菌的添加质量比为1:2~5,两者的添加总量为粗蛋白液总质量的1.0%~2.0%,随后在25~40℃下脱腥处理15~30min;处理后,继续添加活性炭,添加量为粗蛋白液总质量的1.0%~2.0%,在30~50℃下继续脱腥30~60 min,得到脱腥蛋白液;
d、脱腥蛋白液喷雾干燥后,得牡蛎-硒-寡肽蛋白粉,简称牡蛎肽;喷雾干燥条件为进风温度160~200℃,出风温度为60~90℃。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910106561.2A CN109662322A (zh) | 2019-02-02 | 2019-02-02 | 一种保肝护心血管的组合物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910106561.2A CN109662322A (zh) | 2019-02-02 | 2019-02-02 | 一种保肝护心血管的组合物及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN109662322A true CN109662322A (zh) | 2019-04-23 |
Family
ID=66151181
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910106561.2A Pending CN109662322A (zh) | 2019-02-02 | 2019-02-02 | 一种保肝护心血管的组合物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN109662322A (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111357982A (zh) * | 2020-03-16 | 2020-07-03 | 北京中医药大学 | 沙棘复合发酵液及其制备方法、保健饮品、植物酵素 |
CN112715957A (zh) * | 2020-12-04 | 2021-04-30 | 广州音波美健康生物科技有限公司 | 一种解酒护肝的生物小分子肽组合物及其制备方法 |
CN114230635A (zh) * | 2022-02-23 | 2022-03-25 | 华南农业大学 | 一种高活性富硒牡蛎抗氧化肽及其应用 |
CN116687000A (zh) * | 2023-06-28 | 2023-09-05 | 山东天久生物技术有限公司 | 牡蛎肽和雪莲菌活性肽组合物及其制备方法 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103271393A (zh) * | 2013-04-09 | 2013-09-04 | 广东工业大学 | 一种姜黄素和沙棘组成的保健饮料及其制备方法 |
CN104323231A (zh) * | 2014-11-27 | 2015-02-04 | 广州合诚实业有限公司 | 一种护肝醒酒天然组合物及制品与制备方法 |
US20150118336A1 (en) * | 2012-05-02 | 2015-04-30 | China National Research Institute Of Food And Fermentation Industries | Engineered rice having alcoholism relief and liver protection function, and preparation method thereof |
CN108208853A (zh) * | 2018-01-04 | 2018-06-29 | 山东凤凰生物有限公司 | 一种解酒护肝益生菌低聚肽复合制剂及制备方法 |
-
2019
- 2019-02-02 CN CN201910106561.2A patent/CN109662322A/zh active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20150118336A1 (en) * | 2012-05-02 | 2015-04-30 | China National Research Institute Of Food And Fermentation Industries | Engineered rice having alcoholism relief and liver protection function, and preparation method thereof |
CN103271393A (zh) * | 2013-04-09 | 2013-09-04 | 广东工业大学 | 一种姜黄素和沙棘组成的保健饮料及其制备方法 |
CN104323231A (zh) * | 2014-11-27 | 2015-02-04 | 广州合诚实业有限公司 | 一种护肝醒酒天然组合物及制品与制备方法 |
CN108208853A (zh) * | 2018-01-04 | 2018-06-29 | 山东凤凰生物有限公司 | 一种解酒护肝益生菌低聚肽复合制剂及制备方法 |
Non-Patent Citations (4)
Title |
---|
QIUKUAN WANG等: "Novel antioxidative peptides from the protein hydrolysate of oysters (Crassostrea talienwhanensis)", 《FOOD CHEMISTRY》 * |
刘慧等: "牡蛎蛋白酶解液脱腥技术的研究", 《中国食品学报》 * |
吴寿金等: "《现代中草药成分化学》", 30 October 2001, 中国医药科技出版社 * |
蔡东联: "《家庭营养万宝全书》", 31 July 2000, 文汇出版社 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111357982A (zh) * | 2020-03-16 | 2020-07-03 | 北京中医药大学 | 沙棘复合发酵液及其制备方法、保健饮品、植物酵素 |
CN112715957A (zh) * | 2020-12-04 | 2021-04-30 | 广州音波美健康生物科技有限公司 | 一种解酒护肝的生物小分子肽组合物及其制备方法 |
CN114230635A (zh) * | 2022-02-23 | 2022-03-25 | 华南农业大学 | 一种高活性富硒牡蛎抗氧化肽及其应用 |
CN114230635B (zh) * | 2022-02-23 | 2022-05-17 | 华南农业大学 | 一种高活性富硒牡蛎抗氧化肽及其应用 |
CN116687000A (zh) * | 2023-06-28 | 2023-09-05 | 山东天久生物技术有限公司 | 牡蛎肽和雪莲菌活性肽组合物及其制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN109662322A (zh) | 一种保肝护心血管的组合物及其制备方法 | |
KR101594490B1 (ko) | 발효 해삼의 제조방법 및 이로부터 제조된 발효 해삼 | |
KR102118697B1 (ko) | 새싹보리 착즙분말의 제조방법 및 그에 따른 새싹보리 착즙분말 혼합조성물 | |
CN102648751B (zh) | 一种具有解酒护肝功能工程米及其制备方法 | |
Jang et al. | Mung bean coat ameliorates hyperglycemia and the antioxidant status in type 2 diabetic db/db mice | |
JP2006045212A (ja) | 特定のキナ酸誘導体を含有する経口用組成物 | |
Basharat et al. | Nutritional and functional profile of carob bean (Ceratonia siliqua): A comprehensive review | |
CN115025134A (zh) | 一种含有植物乳杆菌的组合物及制备方法与应用 | |
KR101613692B1 (ko) | 감소된 혈당지수를 갖는 현미의 제조방법 | |
Zekarias et al. | Medicinal, nutritional and anti-nutritional properties of cassava (Manihot esculenta): A review | |
CN105124134A (zh) | 一种制备饲料膳食纤维的方法 | |
JP2006238857A (ja) | 醗酵加工野菜 | |
WO2011104971A1 (ja) | 体重増加抑制組成物及びこれを含む食品 | |
JP3370302B2 (ja) | パパイヤを用いた健康食品の製造方法 | |
KR20160140417A (ko) | 천연 추출물을 함유하는 간기능 개선용 조성물 | |
KR100541719B1 (ko) | 소화기능 및 항산화기능이 강화된 생식조성물 | |
JP2010100663A (ja) | タマネギ発酵物を含有する酵素阻害剤 | |
JP4126053B2 (ja) | 鹿角霊芝を含有した健康食品の製造方法 | |
JP2005097222A (ja) | タマネギ発酵物 | |
KR101592938B1 (ko) | 기호성이 향상된 항비만 건강기능성 발효콩 음료 | |
JP2005213211A (ja) | 血糖値上昇抑制剤 | |
Andrade et al. | Fermented grain-based beverages as probiotic vehicles and their potential antioxidant and antidiabetic properties | |
KR101713176B1 (ko) | 항산화 활성을 갖는 한방발효 조성물 및 이의 제조방법 | |
KR101399398B1 (ko) | 액상발효법을 이용한 산마늘 발효물의 제조방법 및 산마늘 발효물을 포함하는 당뇨 또는 당뇨합병증 예방 또는 치료용 조성물 | |
JP2006006156A (ja) | 肝機能強化性健康食品 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190423 |